139 related articles for article (PubMed ID: 34779534)
1. Cancer immunotherapy trial design with random delayed treatment effect and cure rate.
Wu J; Wei J
Stat Med; 2022 Feb; 41(4):786-797. PubMed ID: 34779534
[TBL] [Abstract][Full Text] [Related]
2. Cancer immunotherapy trial design with cure rate and delayed treatment effect.
Wei J; Wu J
Stat Med; 2020 Mar; 39(6):698-708. PubMed ID: 31773770
[TBL] [Abstract][Full Text] [Related]
3. Weighted log-rank test for time-to-event data in immunotherapy trials with random delayed treatment effect and cure rate.
Liu S; Chu C; Rong A
Pharm Stat; 2018 Sep; 17(5):541-554. PubMed ID: 30058101
[TBL] [Abstract][Full Text] [Related]
4. Study design of single-arm phase II immunotherapy trials with long-term survivors and random delayed treatment effect.
Chu C; Liu S; Rong A
Pharm Stat; 2020 Jul; 19(4):358-369. PubMed ID: 31930622
[TBL] [Abstract][Full Text] [Related]
5. Designing cancer immunotherapy trials with delayed treatment effect using maximin efficiency robust statistics.
Ding X; Wu J
Pharm Stat; 2020 Jul; 19(4):424-435. PubMed ID: 32090453
[TBL] [Abstract][Full Text] [Related]
6. Cancer immunotherapy trial design with long-term survivors.
Ding X; Wu J
Pharm Stat; 2021 Jan; 20(1):117-128. PubMed ID: 32869945
[TBL] [Abstract][Full Text] [Related]
7. Sequential monitoring of cancer immunotherapy trial with random delayed treatment effect.
Wu J; Zhu L; Li Y
J Biopharm Stat; 2023 Dec; ():1-14. PubMed ID: 38146192
[TBL] [Abstract][Full Text] [Related]
8. A novel sample size formula for the weighted log-rank test under the proportional hazards cure model.
Xiong X; Wu J
Pharm Stat; 2017 Jan; 16(1):87-94. PubMed ID: 27860138
[TBL] [Abstract][Full Text] [Related]
9. Cancer immunotherapy trial design with delayed treatment effect.
Wu J; Wei J
Pharm Stat; 2020 May; 19(3):202-213. PubMed ID: 31729149
[TBL] [Abstract][Full Text] [Related]
10. Group sequential designs for cancer immunotherapy trial with delayed treatment effect.
Wu J; Li Y; Zhu L
J Biopharm Stat; 2024 Jan; 34(1):1-15. PubMed ID: 36740768
[TBL] [Abstract][Full Text] [Related]
11. A group sequential design and sample size estimation for an immunotherapy trial with a delayed treatment effect.
Li B; Su L; Gao J; Jiang L; Yan F
Stat Methods Med Res; 2021 Mar; 30(3):904-915. PubMed ID: 33357047
[TBL] [Abstract][Full Text] [Related]
12. A weighted log-rank test and associated effect estimator for cancer trials with delayed treatment effect.
Yu C; Huang X; Nian H; He P
Pharm Stat; 2021 May; 20(3):528-550. PubMed ID: 33427400
[TBL] [Abstract][Full Text] [Related]
13. A robust approach to sample size calculation in cancer immunotherapy trials with delayed treatment effect.
Ye T; Yu M
Biometrics; 2018 Dec; 74(4):1292-1300. PubMed ID: 29992543
[TBL] [Abstract][Full Text] [Related]
14. Complex survival trial design by the product integration method.
Tang Y
Stat Med; 2022 Feb; 41(4):798-814. PubMed ID: 34908180
[TBL] [Abstract][Full Text] [Related]
15. A unified approach to power and sample size determination for log-rank tests under proportional and nonproportional hazards.
Tang Y
Stat Methods Med Res; 2021 May; 30(5):1211-1234. PubMed ID: 33819109
[TBL] [Abstract][Full Text] [Related]
16. M&M: A maximum duration design with the Maxcombo test for a group sequential trial of an immunotherapy with a random delayed treatment effect.
Li B; Su L; Ye Y; Yan F
Stat Med; 2022 Feb; 41(4):815-830. PubMed ID: 34783047
[TBL] [Abstract][Full Text] [Related]
17. Designing cancer immunotherapy trials with random treatment time-lag effect.
Xu Z; Park Y; Zhen B; Zhu B
Stat Med; 2018 Dec; 37(30):4589-4609. PubMed ID: 30203592
[TBL] [Abstract][Full Text] [Related]
18. Statistical and practical considerations in designing of immuno-oncology trials.
Mukhopadhyay P; Huang W; Metcalfe P; Öhrn F; Jenner M; Stone A
J Biopharm Stat; 2020 Nov; 30(6):1130-1146. PubMed ID: 33706684
[TBL] [Abstract][Full Text] [Related]
19. Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard.
Wang Z; Zhang Q; Xue A; Whitmore J
Pharm Stat; 2024; 23(3):325-338. PubMed ID: 38152873
[TBL] [Abstract][Full Text] [Related]
20. Sample size calculation for the proportional hazards cure model.
Wang S; Zhang J; Lu W
Stat Med; 2012 Dec; 31(29):3959-71. PubMed ID: 22786805
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
